NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

23 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-25

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase II clinical trial using risk-adapted therapy. The treatment is acute lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months. Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone marrow/peripheral blood lymphoma cells involvement at diagnosis for B-lymphoblastic lymphoma.

The Primary Objective of this study is:

To improve the outcome of children with lymphoblastic lymphoma (LL) who have minimal disseminated disease (MDD) equal to or more than 1% at diagnosis by using MDD- and minimal residual disease (MRD)- based risk-adapted therapy.

The Secondary Objectives of this study are:

* To estimate the event-free survival and overall survival of children with lymphoblastic lymphoma who are treated with MDD- or MRD-based risk- directed therapy.
* To evaluate the prognostic value of levels of MDD at diagnosis and MRD on day 8 of remission induction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL

NCT02151903

B-cell Non-Hodgkin Lymphoma

TERMINATED PHASE1/PHASE2

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

NCT00920153

Lymphoma

TERMINATED PHASE3

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

NCT05272384

Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Hodgkin Lymphoma +3 more

RECRUITING PHASE1

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT04673617

Non Hodgkin Lymphoma

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

NCT00481832

Lymphoma, Non-Hodgkin

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

TREATMENT PLAN

Treatment will consist of 3 main phases: remission induction, consolidation \[only for patients with any central nervous system (CNS) disease and/or testicular involvement\], and continuation.

* Induction (6-7 weeks).
* Consolidation for participants with CNS involvement or those with testicular disease only (10 weeks).
* Reintensification - Participants with residual disease any time after induction therapy may receive 1-2 cycles of re-intensification therapy and may proceed to allogeneic stem cell transplant if suitable donor is available.
* Continuation Therapy (98-120 weeks).
* Intrathecal Chemotherapy (days 1 and 15; if needed also on days 8 and 22)

TREATMENT SCHEME

T lymphoblastic lymphoma: bone marrow/peripheral blood (BM/PB) involvement (MDD/MRD): Diagnosis: less than 1%; Day 8: +/- (Stratum 1)

* Induction

* Single dose of Cyclophosphamide
* Steroid: prednisone
* Continuation: 98 weeks

T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than 1%; Day 8: - (Stratum 2)

* Induction

* Fractionated Cyclophosphamide
* Steroid: prednisone
* Continuation : 98 weeks

T lymphoblastic lymphoma: BM/PB involvement (MDD/MRD): Diagnosis: equal to or greater than 1%; Day 8: + (Stratum 3)

* Induction

* Fractionated Cyclophosphamide
* Steroid: prednisone and dexamethasone
* Continuation: 120 weeks

B lymphoblastic lymphoma: Stage I-III (Stratum 1)

* Induction

* Single dose of Cyclophosphamide
* Steroid: prednisone
* Continuation: 98 weeks

B lymphoblastic lymphoma: Stage IV or testicular (Stratum 2)

* Induction

* Fractionated Cyclophosphamide
* Steroid: prednisone
* Continuation: 98 weeks

Patients with CNS or testicular involvement will receive Consolidation therapy prior to continuation therapy and receive extended maintenance therapy (120 weeks).

Any patient with detectable disease (MRD, bone marrow or biopsy of residual mass) at the end of induction may be considered for reintensification and/or hematopoietic stem cell transplantation (HSCT).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoblastic Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Intervention Type DRUG

Given IT.

Etoposide

Intervention Type DRUG

Given IV.

Given IV.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Prednisolone Oncovin® Vincristine sulfate Daunomycin Cerubidine® Pegaspargase Oncaspar® Erwinase® Adriamycin® Cytoxan® Ara-C Cytosar-U® Purine antimetabolite Cl-F-Ara-A CAFdA 2-Chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-9H-purin-6-amine Clofarex Clolar^TM MTX High-dose methotrexate (HD-MTX) 6-MP Purinethol® Decadron® Cortef® VP-16 Vepesid®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of newly diagnosed lymphoblastic lymphoma (patients must have \<25% tumor cells in bone marrow by morphology)
2. Age ≤ 21 years
3. Limited prior therapy, including systemic glucocorticoids for 1 week or less, 1 dose of vincristine, emergency radiation therapy to the mediastinum, and 1 dose of IT chemotherapy. Other circumstances must be cleared by PI or co-PI.
4. Written, informed consent and assent following guidelines of the Institutional Review Board, National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP).

Exclusion Criteria

1. Participants with prior therapy, other than therapy specified in 3 above.
2. Participants who are pregnant or lactating.
3. Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Maximum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No